Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

International Journal of Colorectal Disease

Volumn 26, Issue 2, 2011, Pages 173-181

  Odom, Dawn ^a   Barber, Beth ^b   Bennett, Lee ^a   Peeters, Marc ^c   Zhao, Zhongyun ^b   Kaye, James ^a   Wolf, Michael ^b   Wiezorek, Jeffrey ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b AMGEN INC   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Colorectal cancer; HRQoL; KRAS; Panitumumab; Symptoms

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; EURO QUALITY OF LIFE 6 DIMENSIONS INDEX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL COMPREHENSIVE CANCER NETWORK FUNCTIONAL ASSESSMENT OF CANCER THERAPY COLORECTAL SYMPTOM INDEX; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SELF REPORT; SKIN TOXICITY; SYMPTOM; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HEALTH; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; RAS PROTEINS;

EID: 79951725816     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-010-1112-5     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74-108
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96 (Pubitemid 351521864)
3. Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470-1479
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048 (Pubitemid 350106711)
6. Van Cutsem E, Peeters M, Siena S, Humblet A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664 (Pubitemid 46797944)
7. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324
8. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
9. Amado RG,Wolf M, PeetersM, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
10. Wiseman LR, Lyseng-Williamson KA (2005) Management of metastatic colorectal cancer: defining the role of capecitabine. Dis Manage Health Outcomes 13:137-149 (Pubitemid 40522610)
11. Tappenden P, Jones, R, Paisley S, Carroll C (2007) Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technology Assessment 11:No. 12
12. Byrne C, Griffin A, Blazeby J, Conroy T, Efficace F (2007) Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer. Eur J Surg Oncol 33(Suppl 2):S95-S104 (Pubitemid 350216637)
13. Cella D, Paul D, Yount S, Winn R, Chang CH, Banik D, Weeks J (2003) What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21:526-535 (Pubitemid 37169556)
14. Colwell HH, Mathias SD, Turner MP, Lu J, Wright N, Peeters M, Cella D, Devercelli G (2010) Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. Oncologist 15:308-316
15. Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203-220 (Pubitemid 40353904)
16. Mathias SD, Pritchard ML, Colwell HH, Lu J, Wright N (2006) What is the minimal clinically important difference and responsiveness of a patient-reported outcome questionnaire for metastatic colorectal cancer? Ann Oncol 17: Abstract no. 349P
17. Fitzmaurice GM, Laird N, Ware JH (2004) Applied longitudinal analysis. Wiley, Hoboken
18. Hedeker D, Gibbons RD (1997) Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 2:64
19. Little RJA (1993) Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc 88:125
20. Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469-1474 (Pubitemid 350175845)
21. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115:1544-1554
22. Au H-J, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 11:1822-1828
23. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610-621 (Pubitemid 350012125)
24. Romito F, Giuliani F, Cormio C, Tulipani C, Mattioli V, Colucci G (2010) Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 18:329-334
25. Donaldson GW, Moinpour CM (2005) Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 23:7380-7384 (Pubitemid 46291794)